Abstract
ObjectiveThis phase 2a randomised, double blind, placebo controlled, parallel group study evaluated the safety and efficacy of a first-in-class drug candidate ABX464 (obefazimod, 50 mg and 100 mg per day),...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have